Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of novel therapeutics for the treatment of infectious disease. The Company has pioneered the development of an anti-toxin antibody, ETI-204, for the treatment and prophylaxis of inhalational anthrax disease following a biowarfare attack. ETI-204 has demonstrated activity in multiple studies in nonclinical animal models of inhalational anthrax and has been evaluated in three completed human safety trials.
In December 2009, Elusys received an advanced development contract totaling $143M from the Biomedical Advanced Research and Development Authority (BARDA) of HHS to complete final development of ETI-204 for submission of a BLA application for FDA licensure and procurement in the SNS. In 2011, Elusys was awarded a second BARDA contract ($69M) to evaluate the safety and efficacy of ETI-204 when administered via IM injection. Today we have completed our End of Phase Two meeting with FDA and are initiating three human safety trials to complete our clinical data package in support of BLA filing.
Elusys’ success in the development of ETI-204 has been achieved by our talented team of scientists, project managers, and business professionals who are committed to making ETI-204 available for the protection of civilians and military personnel.